Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 426

1.

The practice of dentistry in intensive care units in Brazil.

Blum DFC, Silva JASD, Baeder FM, Della Bona Á.

Rev Bras Ter Intensiva. 2018 Sep 3. pii: S0103-507X2018000504103. doi: 10.5935/0103-507X.20180044. [Epub ahead of print] Portuguese, English.

2.

Automatic Generation of Figural Analogies With the IMak Package.

Blum D, Holling H.

Front Psychol. 2018 Aug 6;9:1286. doi: 10.3389/fpsyg.2018.01286. eCollection 2018.

3.

The Adenosinergic Signaling: A Complex but Promising Therapeutic Target for Alzheimer's Disease.

Cellai L, Carvalho K, Faivre E, Deleau A, Vieau D, Buée L, Blum D, Mériaux C, Gomez-Murcia V.

Front Neurosci. 2018 Aug 3;12:520. doi: 10.3389/fnins.2018.00520. eCollection 2018. Review.

4.

Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer's Disease.

Faivre E, Coelho JE, Zornbach K, Malik E, Baqi Y, Schneider M, Cellai L, Carvalho K, Sebda S, Figeac M, Eddarkaoui S, Caillierez R, Chern Y, Heneka M, Sergeant N, Müller CE, Halle A, Buée L, Lopes LV, Blum D.

Front Mol Neurosci. 2018 Jul 12;11:235. doi: 10.3389/fnmol.2018.00235. eCollection 2018.

5.

The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease.

Blum D, Chern Y, Domenici MR, Buée L, Lin CY, Rea W, Ferré S, Popoli P.

J Caffeine Adenosine Res. 2018 Jun 1;8(2):43-58. doi: 10.1089/caff.2018.0006. Review.

6.

Hypermetabolism in the cerebellum and brainstem and cortical hypometabolism are independently associated with cognitive impairment in Parkinson's disease.

Blum D, la Fougère C, Pilotto A, Maetzler W, Berg D, Reimold M, Liepelt-Scarfone I.

Eur J Nucl Med Mol Imaging. 2018 Jul 14. doi: 10.1007/s00259-018-4085-1. [Epub ahead of print]

PMID:
30008111
7.

Age-related shift in LTD is dependent on neuronal adenosine A2A receptors interplay with mGluR5 and NMDA receptors.

Temido-Ferreira M, Ferreira DG, Batalha VL, Marques-Morgado I, Coelho JE, Pereira P, Gomes R, Pinto A, Carvalho S, Canas PM, Cuvelier L, Buée-Scherrer V, Faivre E, Baqi Y, Müller CE, Pimentel J, Schiffmann SN, Buée L, Bader M, Outeiro TF, Blum D, Cunha RA, Marie H, Pousinha PA, Lopes LV.

Mol Psychiatry. 2018 Jun 27. doi: 10.1038/s41380-018-0110-9. [Epub ahead of print]

PMID:
29950682
8.

Modeling and simulations to support dose selection for eslicarbazepine acetate therapy in pediatric patients with partial-onset seizures.

Sunkaraneni S, Ludwig E, Fiedler-Kelly J, Hopkins S, Galluppi G, Blum D.

J Pharmacokinet Pharmacodyn. 2018 Aug;45(4):649-658. doi: 10.1007/s10928-018-9596-7. Epub 2018 Jun 9.

9.

Increased Protein Tyrosine Phosphatase 1B (PTP1B) Activity and Cardiac Insulin Resistance Precede Mitochondrial and Contractile Dysfunction in Pressure-Overloaded Hearts.

Nguyen TD, Schwarzer M, Schrepper A, Amorim PA, Blum D, Hain C, Faerber G, Haendeler J, Altschmied J, Doenst T.

J Am Heart Assoc. 2018 Jun 21;7(13). pii: e008865. doi: 10.1161/JAHA.118.008865.

10.

Iatrogenesis Imperfecta Medicamentosa: Adverse Drug Events in Dialysis Patients are Associated with Higher Resource Utilization and Mortality.

Blum D, Chan CT.

Am J Nephrol. 2018;47(6):438-440. doi: 10.1159/000489704. Epub 2018 Jun 12. No abstract available.

11.

Thyroid Hormone Supplementation Restores Spatial Memory, Hippocampal Markers of Neuroinflammation, Plasticity-Related Signaling Molecules, and β-Amyloid Peptide Load in Hypothyroid Rats.

Chaalal A, Poirier R, Blum D, Laroche S, Enderlin V.

Mol Neurobiol. 2018 May 23. doi: 10.1007/s12035-018-1111-z. [Epub ahead of print]

PMID:
29796989
12.

Exposure-safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate.

Gidal BE, Jacobson MP, Ben-Menachem E, Carreño M, Blum D, Soares-da-Silva P, Falcão A, Rocha F, Moreira J, Grinnell T, Ludwig E, Fiedler-Kelly J, Passarell J, Sunkaraneni S.

Acta Neurol Scand. 2018 Sep;138(3):203-211. doi: 10.1111/ane.12950. Epub 2018 May 6.

13.

Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?

Laurent C, Buée L, Blum D.

Biomed J. 2018 Feb;41(1):21-33. doi: 10.1016/j.bj.2018.01.003. Epub 2018 Mar 20. Review.

14.

Adenosine Augmentation Evoked by an ENT1 Inhibitor Improves Memory Impairment and Neuronal Plasticity in the APP/PS1 Mouse Model of Alzheimer's Disease.

Lee CC, Chang CP, Lin CJ, Lai HL, Kao YH, Cheng SJ, Chen HM, Liao YP, Faivre E, Buée L, Blum D, Fang JM, Chern Y.

Mol Neurobiol. 2018 Apr 4. doi: 10.1007/s12035-018-1030-z. [Epub ahead of print]

PMID:
29616397
15.

Novel Lipidized Analog of Prolactin-Releasing Peptide Improves Memory Impairment and Attenuates Hyperphosphorylation of Tau Protein in a Mouse Model of Tauopathy.

Popelová A, Pražienková V, Neprašová B, Kasperová BJ, Hrubá L, Holubová M, Zemenová J, Blum D, Železná B, Galas MC, Kuneš J, Maletínská L.

J Alzheimers Dis. 2018;62(4):1725-1736. doi: 10.3233/JAD-171041.

PMID:
29614684
16.

Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures.

Andermann E, Biton V, Benbadis SR, Shneker B, Shah AK, Carreño M, Trinka E, Ben-Menachem E, Biraben A, Rocha F, Gama H, Cheng H, Blum D; Study 301, 302 and 304 Investigators.

Epilepsy Behav. 2018 May;82:119-127. doi: 10.1016/j.yebeh.2017.12.017. Epub 2018 Mar 28.

17.

Incidence of seizure exacerbation and seizures reported as adverse events during adjunctive treatment with eslicarbazepine acetate: A pooled analysis of three Phase III controlled trials.

Carreño M, Benbadis S, Rocha F, Blum D, Cheng H; Study 301, 302 and 304 Investigators (Appendix 1).

Epilepsia Open. 2017 Nov 9;2(4):459-466. doi: 10.1002/epi4.12083. eCollection 2017 Dec.

18.

Population Pharmacokinetics and Exposure-Response Analyses of Eslicarbazepine Acetate Efficacy and Safety in Monotherapy of Partial-Onset Seizures.

Sunkaraneni S, Ludwig EA, Passarell JA, Blum D, Grinnell T, Fiedler-Kelly J.

J Clin Pharmacol. 2018 Jul;58(7):927-938. doi: 10.1002/jcph.1086. Epub 2018 Mar 12.

PMID:
29528499
19.

Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs.

Mintzer S, Wechsler RT, Rogin JB, Gidal BE, Schwab M, Ben-Menachem E, Carreño M, da Silva PS, Moreira J, Li Y, Blum D, Grinnell T.

Epilepsy Res. 2018 Mar;141:83-89. doi: 10.1016/j.eplepsyres.2018.02.001. Epub 2018 Feb 9.

20.

Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine.

Pazdera L, Sperling MR, Harvey JH, Sam MC, Strom LA, Blum D, Grinnell T, Cheng H.

Epilepsia. 2018 Mar;59(3):704-714. doi: 10.1111/epi.14014. Epub 2018 Feb 16.

PMID:
29450890
21.

Mutual Relationship between Tau and Central Insulin Signalling: Consequences for AD and Tauopathies?

Gratuze M, Joly-Amado A, Vieau D, Buée L, Blum D.

Neuroendocrinology. 2018;107(2):181-195. doi: 10.1159/000487641. Epub 2018 Feb 13.

22.

Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism.

Vercruysse P, Vieau D, Blum D, Petersén Å, Dupuis L.

Front Mol Neurosci. 2018 Jan 19;11:2. doi: 10.3389/fnmol.2018.00002. eCollection 2018. Review.

23.

Tacrolimus-induced nephrotoxicity in mice is associated with microRNA deregulation.

Vandenbussche C, Van der Hauwaert C, Dewaeles E, Franczak J, Hennino MF, Gnemmi V, Savary G, Tavernier Q, Nottet N, Paquet A, Perrais M, Blum D, Mari B, Pottier N, Glowacki F, Cauffiez C.

Arch Toxicol. 2018 Apr;92(4):1539-1550. doi: 10.1007/s00204-018-2158-3. Epub 2018 Jan 23.

PMID:
29362864
24.

Replication Study: Transcriptional amplification in tumor cells with elevated c-Myc.

Lewis LM, Edwards MC, Meyers ZR, Talbot CC Jr, Hao H, Blum D; Reproducibility Project: Cancer Biology, Iorns E, Tsui R, Denis A, Perfito N, Errington TM.

Elife. 2018 Jan 9;7. pii: e30274. doi: 10.7554/eLife.30274.

25.

Atypical, non-standard functions of the microtubule associated Tau protein.

Sotiropoulos I, Galas MC, Silva JM, Skoulakis E, Wegmann S, Maina MB, Blum D, Sayas CL, Mandelkow EM, Mandelkow E, Spillantini MG, Sousa N, Avila J, Medina M, Mudher A, Buee L.

Acta Neuropathol Commun. 2017 Nov 29;5(1):91. doi: 10.1186/s40478-017-0489-6. Review.

26.

Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials.

Krauss G, Biton V, Harvey JH, Elger C, Trinka E, Soares da Silva P, Gama H, Cheng H, Grinnell T, Blum D.

Epilepsy Res. 2018 Jan;139:1-8. doi: 10.1016/j.eplepsyres.2017.10.021. Epub 2017 Nov 4.

27.

Influence of dentistry professionals and oral health assistance protocols on intensive care unit nursing staff. A survey study.

Blum DFC, Munaretto J, Baeder FM, Gomez J, Castro CPP, Bona ÁD.

Rev Bras Ter Intensiva. 2017 Jul-Sep;29(3):391-393. doi: 10.5935/0103-507X.20170049. Portuguese, English. No abstract available.

28.

[Tau and cognitive disorders: a role for T lymphocytes].

Laurent C, Dorothée G, Hunot S, Martin E, Delarasse C, Buée L, Blum D.

Med Sci (Paris). 2017 Oct;33(10):817-819. doi: 10.1051/medsci/20173310002. Epub 2017 Oct 10. French. No abstract available.

29.

Population Pharmacokinetic Evaluation and Missed-Dose Simulations for Eslicarbazepine Acetate Monotherapy in Patients With Partial-Onset Seizures.

Sunkaraneni S, Blum D, Ludwig E, Chudasama V, Fiedler-Kelly J, Marvanova M, Bainbridge J, Phillips L.

Clin Pharmacol Drug Dev. 2018 Mar;7(3):287-297. doi: 10.1002/cpdd.382. Epub 2017 Sep 7.

PMID:
28881418
30.

Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy.

Sunkaraneni S, Passarell JA, Ludwig EA, Fiedler-Kelly J, Pitner JK, Grinnell TA, Blum D.

Clin Pharmacol. 2017 Jun 27;9:65-72. doi: 10.2147/CPAA.S133815. eCollection 2017.

31.

Design, synthesis and evaluation of 2-aryl benzoxazoles as promising hit for the A2A receptor.

Duroux R, Renault N, Cuelho JE, Agouridas L, Blum D, Lopes LV, Melnyk P, Yous S.

J Enzyme Inhib Med Chem. 2017 Dec;32(1):850-864. doi: 10.1080/14756366.2017.1334648.

PMID:
28661196
32.

Tau deletion promotes brain insulin resistance.

Marciniak E, Leboucher A, Caron E, Ahmed T, Tailleux A, Dumont J, Issad T, Gerhardt E, Pagesy P, Vileno M, Bournonville C, Hamdane M, Bantubungi K, Lancel S, Demeyer D, Eddarkaoui S, Vallez E, Vieau D, Humez S, Faivre E, Grenier-Boley B, Outeiro TF, Staels B, Amouyel P, Balschun D, Buee L, Blum D.

J Exp Med. 2017 Aug 7;214(8):2257-2269. doi: 10.1084/jem.20161731. Epub 2017 Jun 26.

33.

The applicability of a weight loss grading system in cancer cachexia: a longitudinal analysis.

Vagnildhaug OM, Blum D, Wilcock A, Fayers P, Strasser F, Baracos VE, Hjermstad MJ, Kaasa S, Laird B, Solheim TS; European Palliative Care Cancer Symptom study group.

J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):789-797. doi: 10.1002/jcsm.12220. Epub 2017 Jun 18.

34.

Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters.

Gidal BE, Mintzer S, Schwab M, Schutz R, Kharidia J, Blum D, Grinnell T, Sunkaraneni S.

Epilepsy Res. 2017 Sep;135:64-70. doi: 10.1016/j.eplepsyres.2017.05.005. Epub 2017 May 18.

PMID:
28624574
35.

Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials.

Biton V, Rogin JB, Krauss G, Abou-Khalil B, Rocha JF, Moreira J, Gama H, Trinka E, Elger CE, Cheng H, Grinnell T, Blum D; Study 301, 302 and 304 Investigators.

Epilepsy Behav. 2017 Jul;72:127-134. doi: 10.1016/j.yebeh.2017.04.019. Epub 2017 Jun 7.

36.

Home-Based Physical Behavior in Late Stage Parkinson Disease Dementia: Differences between Cognitive Subtypes.

Cerff B, Maetzler W, Sulzer P, Kampmeyer M, Prinzen J, Hobert MA, Blum D, van Lummel R, Del Din S, Gräber S, Berg D, Liepelt-Scarfone I.

Neurodegener Dis. 2017;17(4-5):135-144. doi: 10.1159/000460251. Epub 2017 Apr 26.

PMID:
28441649
37.

Dual role of MUC1 mucin in kidney ischemia-reperfusion injury: Nephroprotector in early phase, but pro-fibrotic in late phase.

Gibier JB, Hémon B, Fanchon M, Gaudelot K, Pottier N, Ringot B, Van Seuningen I, Glowacki F, Cauffiez C, Blum D, Copin MC, Perrais M, Gnemmi V.

Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1336-1349. doi: 10.1016/j.bbadis.2017.03.023. Epub 2017 Mar 31.

PMID:
28366875
38.

Impact of seizure frequency reduction on health-related quality of life among clinical trial subjects with refractory partial-onset seizures: A pooled analysis of phase III clinical trials of eslicarbazepine acetate.

Velez FF, Bond TC, Anastassopoulos KP, Wang X, Sousa R, Blum D, Cramer JA.

Epilepsy Behav. 2017 Mar;68:203-207. doi: 10.1016/j.yebeh.2016.10.027. Epub 2017 Feb 23.

PMID:
28236698
39.

Omics analysis of mouse brain models of human diseases.

Paban V, Loriod B, Villard C, Buee L, Blum D, Pietropaolo S, Cho YH, Gory-Faure S, Mansour E, Gharbi A, Alescio-Lautier B.

Gene. 2017 Feb 5;600:90-100. doi: 10.1016/j.gene.2016.11.022. Epub 2016 Nov 18.

PMID:
27871923
40.

Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy.

Laurent C, Dorothée G, Hunot S, Martin E, Monnet Y, Duchamp M, Dong Y, Légeron FP, Leboucher A, Burnouf S, Faivre E, Carvalho K, Caillierez R, Zommer N, Demeyer D, Jouy N, Sazdovitch V, Schraen-Maschke S, Delarasse C, Buée L, Blum D.

Brain. 2017 Jan;140(1):184-200. doi: 10.1093/brain/aww270. Epub 2016 Nov 5.

41.

Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections.

Gilchuk I, Gilchuk P, Sapparapu G, Lampley R, Singh V, Kose N, Blum DL, Hughes LJ, Satheshkumar PS, Townsend MB, Kondas AV, Reed Z, Weiner Z, Olson VA, Hammarlund E, Raue HP, Slifka MK, Slaughter JC, Graham BS, Edwards KM, Eisenberg RJ, Cohen GH, Joyce S, Crowe JE Jr.

Cell. 2016 Oct 20;167(3):684-694.e9. doi: 10.1016/j.cell.2016.09.049.

42.

The caffeine-binding adenosine A2A receptor induces age-like HPA-axis dysfunction by targeting glucocorticoid receptor function.

Batalha VL, Ferreira DG, Coelho JE, Valadas JS, Gomes R, Temido-Ferreira M, Shmidt T, Baqi Y, Buée L, Müller CE, Hamdane M, Outeiro TF, Bader M, Meijsing SH, Sadri-Vakili G, Blum D, Lopes LV.

Sci Rep. 2016 Aug 11;6:31493. doi: 10.1038/srep31493.

43.

A new dual-collimation batch reactor for determination of ultraviolet inactivation rate constants for microorganisms in aqueous suspensions.

Martin SB Jr, Schauer ES, Blum DH, Kremer PA, Bahnfleth WP, Freihaut JD.

J Photochem Photobiol B. 2016 Sep;162:674-680. doi: 10.1016/j.jphotobiol.2016.07.028. Epub 2016 Jul 25.

44.

Drip irrigation uptake in traditional irrigated fields: The edaphological impact.

Puy A, García Avilés JM, Balbo AL, Keller M, Riedesel S, Blum D, Bubenzer O.

J Environ Manage. 2017 Nov 1;202(Pt 3):550-561. doi: 10.1016/j.jenvman.2016.07.017. Epub 2016 Jul 15.

PMID:
27424883
45.

Increased tauopathy drives microglia-mediated clearance of beta-amyloid.

Chen W, Abud EA, Yeung ST, Lakatos A, Nassi T, Wang J, Blum D, Buée L, Poon WW, Blurton-Jones M.

Acta Neuropathol Commun. 2016 Jun 23;4(1):63. doi: 10.1186/s40478-016-0336-1.

46.

Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: A Phase I randomized controlled trial.

Levy-Cooperman N, Schoedel KA, Chakraborty B, Blum D, Cheng H.

Epilepsy Behav. 2016 Aug;61:63-71. doi: 10.1016/j.yebeh.2016.05.010. Epub 2016 Jun 15.

47.

Reflections on monotherapy trials for epilepsy - Authors' reply.

French JA, Mintzer S, Perucca E, Blum DE, Cramer JA, Messenheimer JA, Baulac M.

Lancet Neurol. 2016 Jun;15(7):657-658. doi: 10.1016/S1474-4422(16)00119-8. Epub 2016 May 9. No abstract available.

PMID:
27302226
48.

A Pharmacokinetic Study Comparing Eslicarbazepine Acetate Administered Orally as a Crushed or Intact Tablet in Healthy Volunteers.

Sunkaraneni S, Kharidia J, Schutz R, Blum D, Cheng H.

Clin Pharmacol Drug Dev. 2016 Jul;5(4):278-84. doi: 10.1002/cpdd.242. Epub 2016 Feb 8.

PMID:
27249205
49.

Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies.

Sperling MR, French J, Jacobson MP, Pazdera L, Gough M, Cheng H, Grinnell T, Blum D; Study 045 and 046 Investigators.

Neurology. 2016 Mar 22;86(12):1095-102. doi: 10.1212/WNL.0000000000002497. Epub 2016 Feb 24.

50.

MRNA Levels of ACh-Related Enzymes in the Hippocampus of THY-Tau22 Mouse: A Model of Human Tauopathy with No Signs of Motor Disturbance.

García-Gómez BE, Fernández-Gómez FJ, Muñoz-Delgado E, Buée L, Blum D, Vidal CJ.

J Mol Neurosci. 2016 Apr;58(4):411-5. doi: 10.1007/s12031-015-0699-y. Epub 2015 Dec 23.

PMID:
26697857

Supplemental Content

Support Center